Aim to create disease-modifying medicines that can be delivered to tissues beyond the liver, to which most gene editing treatments are currently limited.
Provides Regeneron with rights to develop additional CRISPR/Cas9-based therapeutic targets and to jointly develop potential products for hemophilia A and B.
VelociSuite technologies facilitate rapid generation of optimized antibodies allowing for cell line production and large-scale bioreactor manufacturing
Isolates hundreds of virus-neutralizing, human antibodies; will prepare manufacturing-ready cell lines so that clinical-scale production can begin immediately.
Karen Bossert comes with 30 years of experience in pharmaceutical manufacturing operations, specializing in aseptic processing, lyophilization and more
Angi Calkins has served in senior leadership roles at Regeneron Pharmaceuticals, a leading biotechnology company that doubled in size during her time there